Weight-loss drugs, such as Ozempic and Wegovy, are gaining popularity in the US, despite concerns about long-term effects and potential harm. Wall Street forecasts sales potential reaching $100 billion. The use of these drugs has also transformed the understanding of obesity, leading to new treatment plans. Chinese regulators have warned about misleading information from pharmaceutical companies regarding weight-loss drugs. The popularity of these drugs is also impacting consumer stock flows and US restaurants' weak traffic. Amid these developments, Chipotle reported strong Q3 earnings and forecasted an acceleration in the fourth quarter, with its CEO expressing confidence in the chain's positioning amidst the growing use of weight-loss drugs. The company's shares rose following the announcement, and the chain is banking on its 'real food' strategy to appeal to weight-loss drug users. Chipotle's Q3 revenue reached $2.5 billion, with an operating margin of 16%, up from 15.1%. A new trial is set to test whether weight-loss drugs can work without shedding muscle mass. Healthcare companies are trying to convince investors that these drugs won't shrink their businesses. Pharma services firms are rushing to snap up business related to weight-loss drugs. Meanwhile, concerns about shortages of weight-loss drugs like Wegovy are emerging, with Novo investors seeking clarity.
Chipotle thinks people using Ozempic and other drugs to lose weight will want the chain's "real" food over fried alternatives https://t.co/aqSdyDtfM1
$NVO $LLY $WST $TMO $CTLT Weight-loss drugs in spotlight as pharma services firms rush to snap up business - Reuters https://t.co/ep4fWKuHKu
Weight-loss drugs in spotlight as pharma services firms rush to snap up business https://t.co/7qeGvbDcXm https://t.co/xfUHMAK9YF
Healthcare companies who profit from treating obese and overweight patients are trying to convince investors that powerful new weight-loss drugs won't shrink their businesses https://t.co/pulgeef1gr
Novo investors seek clarity on Wegovy weight-loss drug shortages https://t.co/DoVaKS5L3Z https://t.co/6Sy0YTT1sv
New Trial Will Test Whether Weight Loss Drugs Can Work Without Shedding Muscle Mass https://t.co/ZzXcrv2mLO
Healthcare companies who profit from treating obese and overweight patients are trying to convince investors that powerful new weight-loss drugs won't shrink their businesses. More here: https://t.co/zsxs3IUhRZ
Healthcare companies who profit from treating obese and overweight patients are trying to convince investors that powerful new weight-loss drugs won't shrink their businesses https://t.co/3kLAjup4jd
WEIGHT-LOSS DRUG WORRIES ADD TO US RESTAURANTS' WEAK TRAFFIC (Reuters) Investors look for signs that U.S. fast-food chains, already contending with inflation-stung consumers preferring to dine at home, will also have to grapple with the explosive popularity of weight-loss drugs. https://t.co/PkeWI9grHm
Chipotle quarterly results shine as burrito cravings defy high prices https://t.co/qidOnZbQpR https://t.co/zgNoCuRfBv
$CMG Comparable Restaurant Sales Growth https://t.co/WM8c7WCAJl
Live news: Chipotle ‘well positioned’ for growing use of weight-loss drugs, says chief executive https://t.co/ZCE0nQIi3i
Chipotle Mexican Grill Inc. shares rose after its sales beat expectations and the burrito chain forecast an acceleration in the fourth quarter. https://t.co/bSOkb5nCAe
Chipotle reported its third quarter earnings results on Thursday after the market close, beating estimates on its earnings and same-store sales. $CMG https://t.co/lL7n0TRbyQ by @BrookeDiPalma https://t.co/gG8DcLXj9I
$CMG Chipotle beats on eps, beats on rev. Comps +5%. Stock +4.5% AH https://t.co/FGU2VXt8OX
$CMG | Chipotle Mexican Grill Q3 Earning: - Adj. EPS $11.36 (Est. $10.55) - Total Revenue $2.5B (Est. $2.47B) - Comparable Restaurant Sales Increased 5% - Operating Margin 16%, Up From 15.1% - Sees Q4 Comparable Restaurant Sales Growing In Mid To High-Single Digit Rage
Chipotle comps up 5%. Restaurant level operating margin 26.3% up 100bp. $CMG
$CMG Chipotle reports earnings AH Will be a large focus on any ozempic affects Data showing resilience though with $MCD (reporting Monday) taking a hit. https://t.co/fSkrYyLJvp
New Trial Will Test Whether Weight Loss Drugs Can Work Without Shedding Muscle Mass https://t.co/dTkF6AVTjR https://t.co/BfJFo3ymsy
Weight-loss drug worries add to US restaurants' weak traffic woes https://t.co/ECV7HgN4TB https://t.co/B0lWUCJRVs
Weight-loss drug worries add to US restaurants' weak traffic woes https://t.co/ktJyCVrbM5 https://t.co/55JVSD8Ule
The buzz around new weight-loss drugs that sent the stock of several Chinese pharmaceutical companies skyrocketing has deflated somewhat after regulators warned that some firms had misled investors about their products. https://t.co/0A83oCf92Y
Americans are so desperate to get their hands on popular weight-loss drugs such as Ozempic and Wegovy that many are turning to knockoff versions, Leana S. Wen writes. "Doing so could come with real harm." https://t.co/HIwh2UfQwu https://t.co/HlbsKp88bX
Boss of OIive Garden parent company Darden Restaurants shrugs off concerns that weight loss drug Ozempic could tank demand - after Walmart reported customers on appetite suppressants 'pulling back' https://t.co/Cb9sjT79lO
Powerful weight-loss drugs have transformed our understanding of obesity. Now, doctors are writing new game plans for whom to treat with the drugs and when. https://t.co/3DoLuAI5xw
New drugs could spell an end to the world’s obesity epidemic. The long-term effects must be carefully studied—but the excitement is justified https://t.co/5bAGxsW7Mu👇
Congrats on treating your body like a dumpster... Wall Street hikes forecasts for anti-obesity drug sales to $100 billion and beyond. A look at the numbers https://t.co/vyFeZD6EaF
Weight-loss drugs driving hedge fund consumer stock flows -Goldman Sachs https://t.co/KPD8LunGnI https://t.co/nLzwQHWwii